Many of these markers, such as N-terminal pro-B-type natriuretic peptide (NT-proBNP) [19] and carcinoembryonic antigen 125 (CA125) [18], are routinely used in the clinical management of HF. The gene discussed is NPPB; the disease is hydrops fetalis.